Domainex Ltd. and Cresset Discovery Services, today announced an alliance to provide their customers with world-class laboratory-based and computational drug discovery services through a seamless combination of their respective capabilities in chemistry and biology.
A new £3.4 million programme will develop new tools to understand which interactions between proteins in the human body are relevant to disease.
London, UK and Cambridge, UK, 29th October 2015 / Domainex Ltd. announced today that it is expanding all aspects of its drug discovery service business including biology, analytical chemistry and medicinal chemistry.
London, UK and Cambridge, UK, 20th October 2015 / Domainex Ltd. and Imperial College London today announce a new partnership focused on the discovery of novel therapies to treat myocardial infarction, also known as a heart attack.
Domainex Ltd. is pleased to announce that it is enlisting the support of Shin Kitaoka of BioGemini Ltd. to provide advice on expansion into the Japanese market
Domainex and Auspherix today announce an expansion of their collaboration to develop new drugs to tackle the growing threat of resistance to antibiotics. The programme has been extended through to 2017.
Current Challenges, Novel Tools and Emerging Targets with Trevor Perrior, Ph.D., Director, Research, Domainex Limited Gregg Siegal, Ph.D., CEO, ZoBio
Domainex Ltd, a private drug discovery service company, today announces that it is launching an integrated bioassay service platform, BioassayBuilder.
Barry Knight is a Chartered Accountant and brings extensive financial expertise to Domainex, having been an executive director for Life Sciences companies for more than 25 years. Barry was previously Finance Director of both Trigen Holdings plc and AIM-listed Fulcrum Pharma plc.
Domainex CSO, Prof Laurence Pearl, wins prestigious CRUK Translational Research Award